Edwards Lifesciences (EW) Current Leases (2014 - 2026)

Edwards Lifesciences has reported Current Leases for 9 years, with the latest figure at $24.1 million in Q2 2026.

• On a quarterly basis, Current Leases fell 6.95% year-over-year to $24.1 million in Q2 2026; TTM through Jun 2026 was $24.1 million, a 6.95% decrease from a year earlier, with the FY2025 full-year figure at $24.5 million, up 4.7% from the prior year.
• Current Leases was $24.1 million for Q2 2026 at Edwards Lifesciences, down from $24.3 million in the prior quarter.
• The five-year high for Current Leases was $26.8 million in Q3 2025, with the low at $21.5 million in Q2 2024.
• Average Current Leases over 5 years is $24.2 million, with a median of $24.2 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Current Leases decreased 11.52% in 2024, then advanced 20.47% in 2025.
• Over 5 years, Current Leases stood at $25.5 million in 2022, then slipped by 10.2% to $22.9 million in 2023, then increased by 2.18% to $23.4 million in 2024, then rose by 4.7% to $24.5 million in 2025, then decreased by 1.63% to $24.1 million in 2026.
• The last three Current Leases figures came in at $24.1 million (Q2 2026), $24.3 million (Q1 2026), and $24.5 million (Q4 2025), per Business Quant data.